论文部分内容阅读
用免疫活性细胞输注的过继免疫是肿瘤生物治疗的研究热点之一。此疗法不仅是常规抗肿瘤治疗的补充,更是为晚期不宜手术或无法承受放疗化疗所带来的副作用的患者开辟了一个新的治疗途径,成为人类抗击肿瘤最有希望的战略措施之一。CIK(Cytokine Induced Killer)是继LAK,TIL及CD3AK细胞之后,具有细胞增殖倍数高、肿瘤杀伤能力强等特点的新一代过继免疫抗肿瘤细胞。本文就CIK的特点,抗肿瘤机制,及临床应用现状等作一综述。
Adoptive immunization with immunocompetent cells is one of the hot topics in tumor biotherapy. This therapy is not only a supplement to conventional anti-tumor therapy, but also opens up a new therapeutic approach for patients who are not suitable for advanced surgery or can not afford the side effects caused by radiotherapy and chemotherapy, making them one of the most promising strategic measures for fighting cancer in humans. CIK (Cytokine Induced Killer) is a new generation of adoptive immunity antitumor cells after LAK, TIL and CD3AK cells with high cell proliferation rate and strong tumor-killing ability. This article reviews the characteristics of CIK, anti-tumor mechanisms, and clinical application status.